Diagnostic and Prognostic Use of Bone Turnover Markers

Chapter
First Online:
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 192)

Abstract

The use of bone turnover markers in oncology includes monitoring of anticancer treatment in patients with malignant disease metastatic to the bones (therapeutic monitoring), predicting the risk of bone relapse in patients with a first diagnosis of potentially curative, early-stage malignant tumors (prognostic use), and making an early diagnosis of (microscopic) malignant bone disease in patients with a known malignant tumor to start early bone-targeted treatment and avoid skeletal-related events (diagnostic use). Concerning prognostic use, there is limited evidence for bone turnover markers to predict the occurrence of metachronous bone metastases in patients with early-stage malignant tumors, with serum PINP (N-terminal propeptide of procollagen type 1), ICTP (Carboxyterminal cross-linked telopeptide of type I collagen), bone sialoprotein (BSP), and tumor immunoexpression of BSP being the most promising candidates. Concerning diagnostic use, serum bone-specific alkaline phosphatise (BSAP), PINP and osteoprotegerin (OPG) were repeatedly shown to be associated with synchronous bone metastases in patients with breast or lung cancer, but sensitivity of these markers was too low to suggest that they might be preferred over conventional bone scans for the diagnosis of bone metastases. A somewhat higher sensitivity for the diagnosis of bone metastases was found for urinary NTx (N-terminal cross-linked telopeptide of type I collagen) and serum ICTP in solid tumor patients, serum TRAcP-5b (Tartrate-resistant acid phosphatase type 5b) in patients with breast cancer and serum BSAP, PINP and OPG in prostate cancer patients. Both prognostic and diagnostic use of bone turnover markers are reviewed in this chapter.

Keywords

Prostate Cancer Bone Metastasis Zoledronic Acid Bone Turnover Marker Bone Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61:128–134PubMedCrossRefGoogle Scholar
  2. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15:455–459PubMedCrossRefGoogle Scholar
  3. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760–764PubMedCrossRefGoogle Scholar
  4. Bataille R, Delmas PD, Chappard D, Sany J (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66:167–172PubMedCrossRefGoogle Scholar
  5. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRefGoogle Scholar
  6. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350–353PubMedCrossRefGoogle Scholar
  7. Bellahcene A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Menard S, Castronovo V (1997) Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183–188PubMedCrossRefGoogle Scholar
  8. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66:503–513PubMedCrossRefGoogle Scholar
  9. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977–2983PubMedGoogle Scholar
  10. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69PubMedCrossRefGoogle Scholar
  11. Caillot-Augusseau A, Lafage-Proust MH, Soler C, Pernod J, Dubois F, Alexandre C (1998) Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95). Clin Chem 44:578–585PubMedGoogle Scholar
  12. Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333–368PubMedGoogle Scholar
  13. Capeller B, Caffier H, Sutterlin MW, Dietl J (2003) Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23:1011–1015PubMedGoogle Scholar
  14. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62:300–306PubMedCrossRefGoogle Scholar
  15. Chao TY, Ho CL, Lee SH, Chen MM, Janckila A, Yam LT (2004) Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 11:511–516PubMedCrossRefGoogle Scholar
  16. Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46:388–393PubMedCrossRefGoogle Scholar
  17. Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521–2533PubMedCrossRefGoogle Scholar
  18. Coleman J, Brown E, Terpos A, Lipton MR, Smith R, Cook P (2008) Major, bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–639PubMedCrossRefGoogle Scholar
  19. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A (2002) Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850–856PubMedCrossRefGoogle Scholar
  20. Dane F, Turk HM, Sevinc A, Buyukberber S, Camci C, Tarakcioglu M (2008) Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 100:425–428PubMedGoogle Scholar
  21. De Pinieux G, Flam T, Zerbib M, Taupin P, Bellahcene A, Waltregny D, Vieillefond A, Poupon MF (2001) Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J Urol 166:1924–1930PubMedCrossRefGoogle Scholar
  22. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914–3919PubMedGoogle Scholar
  23. Ebert W, Muley T, Herb KP, Schmidt-Gayk H (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24:3193–3201PubMedGoogle Scholar
  24. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G (1994) Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 269:14853–14856PubMedGoogle Scholar
  25. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMedGoogle Scholar
  26. Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1):33–40PubMedGoogle Scholar
  27. Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501–8511PubMedCrossRefGoogle Scholar
  28. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109:24–29PubMedCrossRefGoogle Scholar
  29. Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z (2005) Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90:5765–5768PubMedCrossRefGoogle Scholar
  30. Heuck ]C, Wolthers OD (1998) A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover. J Endocrinol 159:127–131PubMedCrossRefGoogle Scholar
  31. Ikeda I, Miura T, Kondo I (1996) Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 77:102–106PubMedCrossRefGoogle Scholar
  32. Ivaska KK, Pettersson K, Nenonen A, Uusi-Rasi K, Heinonen A, Kannus P, Vaananen HK (2005) Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 51:2362–2365PubMedCrossRefGoogle Scholar
  33. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H’s cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700–13708PubMedCrossRefGoogle Scholar
  34. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696PubMedCrossRefGoogle Scholar
  35. Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J, Blanco G (2001) Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21:2873–2876PubMedGoogle Scholar
  36. Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening SA, Sinha P (2001) Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 47:2061–2063PubMedGoogle Scholar
  37. Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA (2003) Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170:2302–2305PubMedCrossRefGoogle Scholar
  38. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111:783–791PubMedCrossRefGoogle Scholar
  39. Jung K, Lein M, Ringsdorf M, Roigas J, Schnorr D, Loening SA, Staack A (2006) Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176:1326–1331PubMedCrossRefGoogle Scholar
  40. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW (2004) Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956–965PubMedCrossRefGoogle Scholar
  41. Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos KN (2010) Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 27:332–338PubMedCrossRefGoogle Scholar
  42. Keskikuru R, Kataja V, Kosma VM, Eskelinen M, Uusitupa M, Johansson R, Risteli L, Risteli J, Jukkola A (1999) Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Anticancer Res 19:4481–4484PubMedGoogle Scholar
  43. Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87:348–351PubMedCrossRefGoogle Scholar
  44. Koizumi M, Takahashi S, Ogata E (2003) Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23:4095–4099PubMedGoogle Scholar
  45. Kong QQ, Sun TW, Dou QY, Li F, Tang Q, Pei FX, Tu CQ, Chen ZQ (2007) Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22:214–220PubMedGoogle Scholar
  46. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849–853 discussion 853; quiz 1129PubMedCrossRefGoogle Scholar
  47. Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Vaananen HK, Suominen P, Helenius H, Salminen E (2006) Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 26:3127–3132PubMedGoogle Scholar
  48. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32–38PubMedCrossRefGoogle Scholar
  49. Lorente JA, Valenzuela H, Morote J, Gelabert A (1999) Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26:625–632PubMedCrossRefGoogle Scholar
  50. Luftner D, Jozereau D, Schildhauer S, Geppert R, Muller C, Fiolka G, Wernecke KD, Possinger K (2005) PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25:1491–1499PubMedGoogle Scholar
  51. McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T (2010) Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 46:558–565PubMedCrossRefGoogle Scholar
  52. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184–191PubMedGoogle Scholar
  53. Mejjad O, Le Loet X, Basuyau JP, Menard JF, Jego P, Grisot C, Daragon A, Grosbois B, Euller-Ziegler L, Monconduit M (1996) Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d’Etude et de Recherche sur le Myelome (GERM). Eur J Haematol 56:30–34PubMedCrossRefGoogle Scholar
  54. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17:262–270PubMedCrossRefGoogle Scholar
  55. Mori K, Ando K, Heymann D, Redini F (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol 24:235–242PubMedGoogle Scholar
  56. Narita N, Yuasa T, Tsuchiya N, Kumazawa T, Narita S, Inoue T, Ma Z, Saito M, Horikawa Y, Satoh S, Ogawa O, Habuchi T (2008) A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer 8:224PubMedCrossRefGoogle Scholar
  57. Nguyen TV, Meier C, Center JR, Eisman JA, Seibel MJ (2007) Bone turnover in elderly men: relationships to change in bone mineral density. BMC Musculoskelet Disord 8:13PubMedCrossRefGoogle Scholar
  58. Oremek GM, Weis A, Sapoutzis N, Sauer-Eppel H (2003) Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res 23:987–990PubMedGoogle Scholar
  59. Osteomark NTX (2008) Accurate answers for osteoporosis patient management: urine ELISA, serum ELISA. http://www.osteomark.com/UEPerformance.cfm
  60. Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV (2006) Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 24:4818–4824PubMedCrossRefGoogle Scholar
  61. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64:884–886PubMedCrossRefGoogle Scholar
  62. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ (1995) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97–103PubMedCrossRefGoogle Scholar
  63. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Kohn H, Bayer P, Thiebaud D, Ludwig H (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90:3743–3750PubMedGoogle Scholar
  64. Puistola U, Risteli L, Kauppila A, Knip M, Risteli J (1993) Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J Clin Endocrinol Metab 77:178–182PubMedCrossRefGoogle Scholar
  65. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67:330–340PubMedCrossRefGoogle Scholar
  66. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G (2011) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226:780–784PubMedCrossRefGoogle Scholar
  67. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–373PubMedCrossRefGoogle Scholar
  68. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R (1996) Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81:3289–3294PubMedCrossRefGoogle Scholar
  69. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K (1999) Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29:16–22PubMedCrossRefGoogle Scholar
  70. Souberbielle JC (2004) Exploration biologique des osteoporoses. Medicine Nucleaire - Imagerie fonctionelle et metabolique 28(2):77--84Google Scholar
  71. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508PubMedCrossRefGoogle Scholar
  72. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064–1069PubMedCrossRefGoogle Scholar
  73. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, Kanfer E, Goldman JM, Apperley JF, Rahemtulla A (2004) Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 18:1420–1426PubMedCrossRefGoogle Scholar
  74. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A, Syrigos KN (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651–1657PubMedGoogle Scholar
  75. Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA (2006) Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76:67–71PubMedCrossRefGoogle Scholar
  76. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483–2494PubMedCrossRefGoogle Scholar
  77. Tu Q, Zhang J, Fix A, Brewer E, Li YP, Zhang ZY, Chen J (2009) Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 218:135–145PubMedCrossRefGoogle Scholar
  78. Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H, Bauknecht T, Schlebusch H (2001) Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264:186–190PubMedCrossRefGoogle Scholar
  79. Valverde P, Tu Q, Chen J (2005) BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 20:1669–1679PubMedCrossRefGoogle Scholar
  80. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P (2006) Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95:506–514PubMedCrossRefGoogle Scholar
  81. Wada N, Ishii S, Ikeda T, Kitajima M (2004) Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model. Breast Cancer 11:282–287PubMedCrossRefGoogle Scholar
  82. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90:1000–1008PubMedCrossRefGoogle Scholar
  83. Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834–843PubMedCrossRefGoogle Scholar
  84. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84:344–351PubMedCrossRefGoogle Scholar
  85. Wymenga LF, Groenier K, Schuurman J, Boomsma JH, Elferink RO, Mensink HJ (2001) Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int 88:231–235PubMedCrossRefGoogle Scholar
  86. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A (2001) Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633–1637PubMedGoogle Scholar
  87. Zhang JH, Wang J, Tang J, Barnett B, Dickson J, Hahsimoto N, Williams P, Ma W, Zheng W, Yoneda T, Pageau S, Chen J (2004) Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 24:1361–1368PubMedGoogle Scholar
  88. Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X (2010) Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 67:114–119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Medical Oncology and Breast CentreCantonal HospitalSt. GallenSwitzerland

Personalised recommendations